Deck Kelly D.'s Insider Trades & SAST Disclosures
Deck Kelly D.'s most recent trade in Inhibrx Biosciences Inc. was a trade of 175,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Deck Kelly D..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. | Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 17,624 | 0 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 2,087 | 0 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Deck Kelly D. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 1,459 | 14,583 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | D. Kelly Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 625 | 21,250 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | D. Deck Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 416 | 9,167 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | D. Deck Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 396 | 17,624 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 16,777 | 21,243 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 3,113 | 18,130 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 110 | 18,020 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 32,431 | 2,087 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 42,523 | 38,020 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 53,958 | 16,042 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 10,417 | 9,583 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 8,125 | 21,875 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 70,000 | 70,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges